{"count": 18, "results": [{"_id": "35010394", "pmid": 35010394, "pmcid": "PMC8750805", "title": "Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled Trial of Metformin for Antipsychotic-Induced Weight Gain in Patients with First-Episode Psychosis: A Pilot Study", "journal": "Int J Environ Res Public Health", "authors": ["Tang C", "Chua YC", "Abdin E", "Subramaniam M", "Verma S"], "date": "2021-12-23T00:00:00Z", "doi": "10.3390/ijerph19010137", "meta_date_publication": "2021 Dec 23", "meta_volume": "19", "meta_issue": "1", "meta_pages": "", "score": 50267.758, "text_hl": "In this pilot study, we aimed to establish the feasibility of using @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and its effectiveness in managing antipsychotic-induced @DISEASE_Weight_Gain @DISEASE_MESH:D015430 @@@weight gain@@@ in @SPECIES_9606 @@@patients@@@ with @DISEASE_Olfactory_Nerve_Injuries @DISEASE_MESH:D061219 @@@first-episode@@@ @<m>DISEASE_Psychotic_Disorders</m> @DISEASE_MESH:D011618 @@@psychosis@@@ (@<m>DISEASE_Psychotic_Disorders</m> @DISEASE_MESH:D011618 @@@FEP@@@) on follow-up with the Singapore Early @<m>DISEASE_Psychotic_Disorders</m> @DISEASE_MESH:D011618 @@@Psychosis@@@ Intervention Programme in a 24-week, randomized, double-blind, placebo-controlled trial, to ascertain the effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ discontinuation on body weight and evaluate the safety and tolerability of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. ", "citations": {"NLM": "Tang C, Chua YC, Abdin E, Subramaniam M, Verma S. Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled Trial of Metformin for Antipsychotic-Induced Weight Gain in Patients with First-Episode Psychosis: A Pilot Study Int J Environ Res Public Health. 2021 Dec 23;19(1):. PMID: 35010394", "BibTeX": "@article{35010394, title={Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled Trial of Metformin for Antipsychotic-Induced Weight Gain in Patients with First-Episode Psychosis: A Pilot Study}, author={Tang C and Chua YC and Abdin E and Subramaniam M and Verma S}, journal={Int J Environ Res Public Health}, volume={19}, number={1}}"}}, {"_id": "34588212", "pmid": 34588212, "pmcid": "PMC8788031", "title": "Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology", "journal": "Evid Based Ment Health", "authors": ["Fitzgerald I", "O'Connell J", "Keating D", "Hynes C", "McWilliams S", "Crowley EK"], "date": "2022-02-01T00:00:00Z", "doi": "10.1136/ebmental-2021-300291", "meta_date_publication": "2022 Feb", "meta_volume": "25", "meta_issue": "1", "meta_pages": "15-22", "score": 50254.086, "text_hl": "...KHQ 4: should @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ versus usual care or placebo be used in the treatment of AIWG in adults with @<m>DISEASE_Psychotic_Disorders</m> @DISEASE_MESH:D011618 @@@FEP@@@?", "citations": {"NLM": "Fitzgerald I, O'Connell J, Keating D, Hynes C, McWilliams S, Crowley EK. Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology Evid Based Ment Health. 2022 Feb;25(1):15-22. PMID: 34588212", "BibTeX": "@article{34588212, title={Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology}, author={Fitzgerald I and O'Connell J and Keating D and Hynes C and McWilliams S and Crowley EK}, journal={Evid Based Ment Health}, volume={25}, number={1}, pages={15-22}}"}}, {"_id": "37502816", "pmid": 37502816, "pmcid": "PMC10370497", "title": "The potential effect of metformin on cognitive and other symptom dimensions in patients with schizophrenia and antipsychotic-induced weight gain: a systematic review, meta-analysis, and meta-regression", "journal": "Front Psychiatry", "authors": ["Battini V", "Cirnigliaro G", "Leuzzi R", "Rissotto E", "Mosini G", "Benatti B", "Pozzi M", "Nobile M", "Radice S", "Carnovale C", "Dell'Osso B", "Clementi E"], "date": "2023-07-12T00:00:00Z", "doi": "10.3389/fpsyt.2023.1215807", "meta_date_publication": "2023", "meta_volume": "14", "meta_issue": "", "meta_pages": "1215807", "score": 50252.0, "text_hl": "No correlation was seen with the @SPECIES_9606 @@@patients@@@' BMI at baseline, thus indicating no potential differences in the use of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in first-episode @<m>DISEASE_Psychotic_Disorders</m> @DISEASE_MESH:D011618 @@@psychosis@@@ or under chronic treatment with SGAs. ", "citations": {"NLM": "Battini V, Cirnigliaro G, Leuzzi R, Rissotto E, Mosini G, Benatti B, Pozzi M, Nobile M, Radice S, Carnovale C, Dell'Osso B, Clementi E. The potential effect of metformin on cognitive and other symptom dimensions in patients with schizophrenia and antipsychotic-induced weight gain: a systematic review, meta-analysis, and meta-regression Front Psychiatry. 2023;14():1215807. PMID: 37502816", "BibTeX": "@article{37502816, title={The potential effect of metformin on cognitive and other symptom dimensions in patients with schizophrenia and antipsychotic-induced weight gain: a systematic review, meta-analysis, and meta-regression}, author={Battini V and Cirnigliaro G and Leuzzi R and Rissotto E and Mosini G and Benatti B and Pozzi M and Nobile M and Radice S and Carnovale C and Dell'Osso B and Clementi E}, journal={Front Psychiatry}, volume={14}, pages={1215807}}"}}, {"_id": "38199991", "pmid": 38199991, "pmcid": "PMC10781725", "title": "Glucose dysregulation in antipsychotic-naive first-episode psychosis: in silico exploration of gene expression signatures", "journal": "Transl Psychiatry", "authors": ["Lee J", "Xue X", "Au E", "McIntyre WB", "Asgariroozbehani R", "Panganiban K", "Tseng GC", "Papoulias M", "Smith E", "Monteiro J", "Shah D", "Maksyutynska K", "Cavalier S", "Radoncic E", "Prasad F", "Agarwal SM", "Mccullumsmith R", "Freyberg Z", "Logan RW", "Hahn MK"], "date": "2024-01-10T00:00:00Z", "doi": "10.1038/s41398-023-02716-8", "meta_date_publication": "2024 Jan 10", "meta_volume": "14", "meta_issue": "1", "meta_pages": "19", "score": 50248.758, "text_hl": "Finally, we find that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ may be a potential treatment for early @DISEASE_Metabolic_Diseases @DISEASE_MESH:D008659 @@@metabolic dysfunction@@@ intrinsic to @<m>DISEASE_Psychotic_Disorders</m> @DISEASE_MESH:D011618 @@@PSDs@@@.", "citations": {"NLM": "Lee J, Xue X, Au E, McIntyre WB, Asgariroozbehani R, Panganiban K, Tseng GC, Papoulias M, Smith E, Monteiro J, Shah D, Maksyutynska K, Cavalier S, Radoncic E, Prasad F, Agarwal SM, Mccullumsmith R, Freyberg Z, Logan RW, Hahn MK. Glucose dysregulation in antipsychotic-naive first-episode psychosis: in silico exploration of gene expression signatures Transl Psychiatry. 2024 Jan 10;14(1):19. PMID: 38199991", "BibTeX": "@article{38199991, title={Glucose dysregulation in antipsychotic-naive first-episode psychosis: in silico exploration of gene expression signatures}, author={Lee J and Xue X and Au E and McIntyre WB and Asgariroozbehani R and Panganiban K and Tseng GC and Papoulias M and Smith E and Monteiro J and Shah D and Maksyutynska K and Cavalier S and Radoncic E and Prasad F and Agarwal SM and Mccullumsmith R and Freyberg Z and Logan RW and Hahn MK}, journal={Transl Psychiatry}, volume={14}, number={1}, pages={19}}"}}, {"_id": "32571543", "pmid": 32571543, "title": "[Management of cardiovascular co-morbidities in young patients with early onset psychosis: State of the art and therapeutic perspectives].", "journal": "Encephale", "authors": ["Frajerman A", "Morin V", "Chaumette B", "Kebir O", "Krebs MO"], "date": "2020-10-01T00:00:00Z", "doi": "10.1016/j.encep.2020.03.007", "meta_date_publication": "2020 Oct", "meta_volume": "46", "meta_issue": "5", "meta_pages": "390-398", "score": 50243.88, "text_hl": "A meta-analysis about @SPECIES_9606 @@@patients@@@ with a first episode of @<m>DISEASE_Psychotic_Disorders</m> @DISEASE_MESH:D011618 @@@psychosis@@@ (@<m>DISEASE_Psychotic_Disorders</m> @DISEASE_MESH:D011618 @@@FEP@@@) found reduced total and LDL @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@cholesterol@@@ levels and an increased @CHEMICAL_Triglycerides @CHEMICAL_MESH:D014280 @@@triglyceride@@@ level compared to the control population. ", "citations": {"NLM": "Frajerman A, Morin V, Chaumette B, Kebir O, Krebs MO. [Management of cardiovascular co-morbidities in young patients with early onset psychosis: State of the art and therapeutic perspectives]. Encephale. 2020 Oct;46(5):390-398. PMID: 32571543", "BibTeX": "@article{32571543, title={[Management of cardiovascular co-morbidities in young patients with early onset psychosis: State of the art and therapeutic perspectives].}, author={Frajerman A and Morin V and Chaumette B and Kebir O and Krebs MO}, journal={Encephale}, volume={46}, number={5}, pages={390-398}}"}}, {"_id": "33854039", "pmid": 33854039, "pmcid": "PMC8046796", "title": "Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial", "journal": "Transl Psychiatry", "authors": ["Agarwal SM", "Panda R", "Costa-Dookhan KA", "MacKenzie NE", "Treen QC", "Caravaggio F", "Hashim E", "Leung G", "Kirpalani A", "Matheson K", "Chintoh AF", "Kramer CK", "Voineskos AN", "Graff-Guerrero A", "Remington GJ", "Hahn MK"], "date": "2021-04-14T00:00:00Z", "doi": "10.1038/s41398-021-01338-2", "meta_date_publication": "2021 Apr 14", "meta_volume": "11", "meta_issue": "1", "meta_pages": "219", "score": 50240.79, "text_hl": "Our results show that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ improved dysglycemia and @GENE_INS @GENE_3630 @@@insulin@@@ sensitivity, independent of @DISEASE_Weight_Loss @DISEASE_MESH:D015431 @@@weight loss@@@, in a young population with @DISEASE_Prediabetic_State @DISEASE_MESH:D011236 @@@prediabetes@@@/@DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ and @<m>DISEASE_Psychotic_Disorders</m> @DISEASE_MESH:D011618 @@@psychosis@@@ spectrum illness, that is at extremely high risk of early cardiovascular mortality. ", "citations": {"NLM": "Agarwal SM, Panda R, Costa-Dookhan KA, MacKenzie NE, Treen QC, Caravaggio F, Hashim E, Leung G, Kirpalani A, Matheson K, Chintoh AF, Kramer CK, Voineskos AN, Graff-Guerrero A, Remington GJ, Hahn MK. Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial Transl Psychiatry. 2021 Apr 14;11(1):219. PMID: 33854039", "BibTeX": "@article{33854039, title={Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial}, author={Agarwal SM and Panda R and Costa-Dookhan KA and MacKenzie NE and Treen QC and Caravaggio F and Hashim E and Leung G and Kirpalani A and Matheson K and Chintoh AF and Kramer CK and Voineskos AN and Graff-Guerrero A and Remington GJ and Hahn MK}, journal={Transl Psychiatry}, volume={11}, number={1}, pages={219}}"}}, {"_id": "22804349", "pmid": 22804349, "title": "Considering metformin in cardiometabolic protection in psychosis.", "journal": "Acta Psychiatr Scand", "authors": ["Curtis J", "Newall H", "Myles N", "Shiers D", "Samaras K"], "date": "2012-10-01T00:00:00Z", "doi": "10.1111/j.1600-0447.2012.01906.x", "meta_date_publication": "2012 Oct", "meta_volume": "126", "meta_issue": "4", "meta_pages": "302-3", "score": 50075.844, "text_hl": "Considering @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in cardiometabolic protection in @<m>DISEASE_Psychotic_Disorders</m> @DISEASE_MESH:D011618 @@@psychosis@@@.", "citations": {"NLM": "Curtis J, Newall H, Myles N, Shiers D, Samaras K. Considering metformin in cardiometabolic protection in psychosis. Acta Psychiatr Scand. 2012 Oct;126(4):302-3. PMID: 22804349", "BibTeX": "@article{22804349, title={Considering metformin in cardiometabolic protection in psychosis.}, author={Curtis J and Newall H and Myles N and Shiers D and Samaras K}, journal={Acta Psychiatr Scand}, volume={126}, number={4}, pages={302-3}}"}}, {"_id": "27716110", "pmid": 27716110, "pmcid": "PMC5048618", "title": "Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis", "journal": "BMC Psychiatry", "authors": ["de Silva VA", "Suraweera C", "Ratnatunga SS", "Dayabandara M", "Wanniarachchi N", "Hanwella R"], "date": "2016-10-03T00:00:00Z", "doi": "10.1186/s12888-016-1049-5", "meta_date_publication": "2016 Oct 3", "meta_volume": "16", "meta_issue": "1", "meta_pages": "341", "score": 50074.46, "text_hl": "Wu et al. reported that 1 in @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ group and 2 in placebo withdrew due to @<m>DISEASE_Psychotic_Disorders</m> @DISEASE_MESH:D011618 @@@psychosis@@@. ", "citations": {"NLM": "de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis BMC Psychiatry. 2016 Oct 3;16(1):341. PMID: 27716110", "BibTeX": "@article{27716110, title={Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis}, author={de Silva VA and Suraweera C and Ratnatunga SS and Dayabandara M and Wanniarachchi N and Hanwella R}, journal={BMC Psychiatry}, volume={16}, number={1}, pages={341}}"}}, {"_id": "20694127", "pmid": 20694127, "title": "Adjuvant metformin worsens psychosis in schizophrenia: a case report.", "journal": "Prim Care Companion J Clin Psychiatry", "authors": ["Venkatasubramanian G", "Arasappa R", "Rao NP", "Behere RV", "Gangadhar BN"], "date": "2010-01-01T00:00:00Z", "doi": "10.4088/PCC.09l00801yel", "meta_date_publication": "2010", "meta_volume": "12", "meta_issue": "2", "meta_pages": "", "score": 50066.195, "text_hl": "Adjuvant @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ worsens @<m>DISEASE_Psychotic_Disorders</m> @DISEASE_MESH:D011618 @@@psychosis@@@ in @DISEASE_Schizophrenia @DISEASE_MESH:D012559 @@@schizophrenia@@@: a case report.", "citations": {"NLM": "Venkatasubramanian G, Arasappa R, Rao NP, Behere RV, Gangadhar BN. Adjuvant metformin worsens psychosis in schizophrenia: a case report. Prim Care Companion J Clin Psychiatry. 2010;12(2):. PMID: 20694127", "BibTeX": "@article{20694127, title={Adjuvant metformin worsens psychosis in schizophrenia: a case report.}, author={Venkatasubramanian G and Arasappa R and Rao NP and Behere RV and Gangadhar BN}, journal={Prim Care Companion J Clin Psychiatry}, volume={12}, number={2}}"}}, {"_id": "22974204", "pmid": 22974204, "title": "Metformin for schizophrenia: an editorial comment to Curtis J, Newall H, Shiers D, Samaras K. 'Considering metformin in cardiometabolic protection in psychosis'.", "journal": "Acta Psychiatr Scand", "authors": ["Taylor D"], "date": "2012-10-01T00:00:00Z", "doi": "10.1111/j.1600-0447.2012.01907.x", "meta_date_publication": "2012 Oct", "meta_volume": "126", "meta_issue": "4", "meta_pages": "233-4", "score": 50061.785, "text_hl": "'Considering @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in cardiometabolic protection in @<m>DISEASE_Psychotic_Disorders</m> @DISEASE_MESH:D011618 @@@psychosis@@@'.", "citations": {"NLM": "Taylor D. Metformin for schizophrenia: an editorial comment to Curtis J, Newall H, Shiers D, Samaras K. 'Considering metformin in cardiometabolic protection in psychosis'. Acta Psychiatr Scand. 2012 Oct;126(4):233-4. PMID: 22974204", "BibTeX": "@article{22974204, title={Metformin for schizophrenia: an editorial comment to Curtis J, Newall H, Shiers D, Samaras K. 'Considering metformin in cardiometabolic protection in psychosis'.}, author={Taylor D}, journal={Acta Psychiatr Scand}, volume={126}, number={4}, pages={233-4}}"}}]}